Phase 2 Huntington's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Genetic testing (confirmed by the trial's central laboratory) shows a specific mutation in the huntingtin gene — a CAG repeat length of 40 or more.
- Brain scans show a certain level of shrinkage in a part of the brain called the striatum (caudate), based on age-related measurements linked to an early stage of Huntington's disease.
- A standard Huntington's disease movement assessment (called the Total Motor Score) meets or exceeds a certain age-related threshold linked to a specific stage of the disease.
- A measure of daily functioning (called Total Functional Capacity) scores 11 or higher, indicating a relatively high level of independence.
- If taking certain brain or nerve medications (such as cholinesterase inhibitors, memantine, amantadine, or riluzole), the dose must have been stable for at least 12 weeks before joining and is expected to stay the same for the first 12 months of the trial.
- If taking antidepressants or benzodiazepines, the dose must have been stable for at least 12 weeks before joining and is expected to remain unchanged for the first 12 months of the trial.
- If taking antipsychotics or certain movement-control medications (such as tetrabenazine or similar drugs), the dose must have been stable for at least 12 weeks before joining and is expected to stay the same for the first 12 months of the trial.
Who may not be able to join:
- Brain scans show that it would not be safe to place the treatment device into the required brain areas on both sides of the brain, due to the extent of brain shrinkage or other physical features (confirm with trial site).
- Has received a type of treatment called antisense oligonucleotide therapy within the past year.
- Has previously had deep brain stimulation surgery.
- Has previously had, or plans to have, gene therapy, a cell transplant, or any brain surgery during the course of the study.
- Has taken part in another clinical drug trial with a treatment given throughout the body within the past 6 weeks (or longer, depending on how long the drug stays in the body).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-LaRoche
Phone: 888-662-6728
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with Treatment-emergent Adverse Events (TEAEs); Severity of TEAEs; Change from Baseline in Unified Huntington's Disease Rating Scale (UHDRS®) Total Functional Capacity (TFC) Score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.